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Abstract 
In practice, clinicians generally consider anemia (circulating hemoglobin 
concentration  < 120 g.l-1 in non-pregnant females and < 130 g.l-1 in males) as due 
to impaired hemoglobin synthesis or increased erythrocyte loss or destruction. 
Rarely is a rise in plasma volume relative to circulating total hemoglobin mass 
considered as a cause. But does this matter? We explored this issue in patients, 
using the optimized carbon-monoxide rebreathing method to measure 
hemoglobin concentration and thereby calculate plasma volume in healthy 
volunteers, surgical patients, and those with inflammatory bowel disease, chronic 
liver disease or heart failure. 
We studied 109 participants.  Hemoglobin mass correlated well with its 
concentration in the healthy, surgical and inflammatory bowel disease groups (r= 
0.687-0.871, p< 0.001). However, they were poorly related in liver disease (r= 
0.410, p= 0.11) and heart failure patients (r= 0.312, p= 0.16). Here, hemoglobin 
mass explained little of the variance in its concentration (adjusted R2= 0.109 and 
0.052; p= 0.11 and 0.16), whilst plasma volume did (R2 change 0.724 and 0.805 
in heart and liver disease respectively, p<0.0001). Exemplar patients with 
identical (normal or raised) total hemoglobin masses were diagnosed as 
profoundly anemic (or not) depending on differences in plasma volume that had 
not been measured or even considered as a cause.  The traditional inference that 
anemia generally reflects hemoglobin deficiency may be misleading, potentially 
resulting in inappropriate tests and therapeutic interventions to address 
‘hemoglobin deficiency’ not ‘plasma volume excess’. Measurement of total 
hemoglobin mass and plasma volume is now simple, cheap and safe, and its more 
routine use advocated. 
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Introduction  
Anemia is defined as a reduction in the circulating concentration of hemoglobin 
([Hb]) to < 120 g.l-1 in non-pregnant females and < 130 g.l-1 in males.1 
Such reductions can result from the destruction or loss of erythrocytes or a failure 
of their production, or from impaired hemoglobin synthesis. Given its diverse 
etiology, anemia is common, affecting over 1.6 billion people worldwide 2, and is 
associated with impaired functional capacity, reduced quality of life 3, and poorer 
outcome in diverse disease states. 4-9 
 
For all these reasons, circulating hemoglobin concentrations are routinely 
measured in clinical practice. Once anemia is identified, the cause of impaired 
hemoglobin synthesis or erythrocytosis, or of increased red cell loss or 
destruction, is often sought and treatment (either of the underlying cause, or 
through the administration of packed donor red cells) initiated.  
 
However, it is now becoming clear that this approach may be somewhat 
simplistic. The concentration of circulating hemoglobin will depend not just on 
the total circulating quantity of hemoglobin  (total hemoglobin mass, (tHb-
mass)), but also on the volume of plasma (plasma volume, PV) in which it is 
suspended. These factors are not routinely considered separately, or measured, in 
clinical practice and even in experienced hands their estimation is not trivial. 
However, such assessment may be important if the drivers of an altered [Hb]- and 
the appropriate therapeutic response- are to be truly understood. Thus, the 
circulating hemoglobin concentration in athletes matches that in sedentary 
individuals, meaning that a contribution of increased red cell oxygen carriage to 
 5
elite performance was largely dismissed. Then, in 2001, Heinicke and colleagues 
demonstrated that tHb-mass was increased by some 35% in elite endurance 
athletes, [Hb] matching that in the untrained only because PV was expanded to a 
similar degree. 10 
 
Likewise, alterations in the relationship between plasma volume and tHb-mass 
might strongly influence [Hb] in disease states. Anemia is common in diseases 
such as cancer 11, inflammatory bowel disease (IBD) 12, chronic heart failure 
(CHF) 8, chronic kidney disease (CKD) 13 and chronic liver disease (CLD). 14 
Traditionally, this has been considered the result of a reduced tHb-mass. But a 
low [Hb] might also be found when hemoglobin synthesis, erythrocytosis and 
tHb-mass are all entirely normal (or even high), if plasma volume is 
disproportionately expanded. This can occur through disease-related changes in 
global water balance or distribution of body water. Thus, patients with 
inflammatory bowel disease might face enteric blood loss, suppressed 
hemoglobin synthesis or anemia of chronic inflammation; CLD patients may 
likewise lose blood, have an expanded circulating plasma volume due to 
hyperaldosteronism, or face fluid shifts as a result of raised portal venous 
pressure or hypoalbuminemia; and patients with chronic heart failure may suffer 
an increase in circulating volume due to factors including increased renin-
angiotensin-aldosterone axis activity. 15 In contrast, contractions in PV caused by 
pharmacotherapy may mask a fall in tHb-mass by maintaining [Hb]. 16  
 
The extent to which this is true has not been addressed, largely due to historical 
methodological limitations: circulating red cell volume (RCV, ml) or plasma 
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volume has generally have been determined through radiolabelling of red blood 
cells or albumin respectively. 17 Such techniques are costly and time consuming, 
and not without risk, and are thus not routinely deployed unless in special 
circumstances (this method is recommended for disease diagnosis by the 
Polycythemia Rubra Vera Study Group). 18 
 
Such barriers may be overcome through the use of an ‘optimized carbon 
monoxide (CO) rebreathing’ (oCOR) method 19: inhaled CO binds avidly to 
circulating hemoglobin, and the concentration of the resultant COHb complex 
can be readily measured. Knowing the quantity of absorbed CO, tHb-mass can be 
measured and, knowing [Hb], PV calculated.   The method is cheap, simple and 
safe to use- but has only rarely been applied in the clinical setting.   
 
Thus, the relative contributions of PV and tHb-mass to measured [Hb] across 
disease states have not been described. We sought to address this issue.  
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Methods  
This was a prospective, observational clinical study. We studied five groups: 
healthy volunteers (HV), preoperative patients awaiting major surgery and those 
suffering inflammatory bowel disease (IBD), as well as patients in whom 
alterations in plasma volume might more commonly occur (those with chronic 
liver disease, CLD) or chronic heart failure (CHF)). Each participant was studied 
on one occasion between February 2015 and May 2016.   
 
Optimized Carbon Monoxide Rebreathing Method (oCOR) 
The use of CO to determine tHb-mass was first proposed in the late 1800s, with 
refined techniques being published 100 years later. 20 In 2005, Schmidt and 
Prommer reported a simpler and faster technique (described in detail below) 
which also required less blood sampling. 19 It was applied almost exclusively, 
however, in the fields of athletic physiology, and thus failed to come to the 
attention of the bulk of the broader clinical/medical community.  
 
tHb-mass was determined using the validated oCOR method described in detail 
by Schmidt and Prommer. 19 In brief, COHb concentration in blood was 
measured before and after 2-min rebreathing a known CO volume (0.5 to 1.0 
ml.kg-1 in this study depending on gender). Each participant was seated for 15 
minutes to allow stabilization of plasma volume, after which a mouthpiece 
connected them via a container of  ‘soda lime’~10g (carbon dioxide scrubber) to 
a spirometer (Spico-CO Respirations-Applikator, Blood Tec, Germany) and a 3 
liter anaesthetic bag pre-filled with 100% oxygen. The patient exhaled to residual 
volume, breathed in the CO dose via the spirometer, held their breath for 10 s, 
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then continued normal breathing into the closed circuit via the spirometer for 1 
min 50s.  The participant then exhaled to residual volume, this exhaled volume 
being collected and analyzed to quantify the CO not absorbed into the 
bloodstream. Disconnected from the mouthpiece, participants finally fully 
exhaled to residual volume into a CO gas analyzer (Dra ger Pac 7000, 
Dra egerwerk AG & Co. KGaA, Germany) before and at minutes 4 after CO 
rebreathing, to determine the CO concentration exhaled after disconnecting the 
patient from the spirometer that will also have not been adsorbed into the blood. 
 
 
Statistical Analysis 
Statistical analysis was performed using SPSS Statistics (Version 23.0 for Apple 
Macintosh, Chicago, IL, USA). Values are presented as mean ± standard 
deviation (SD), unless otherwise stated.  Median and interquartile range (IQR) 
are reported when variables were not normally distributed. Categorical variables 
are presented as frequency (%). Pearson’s correlation coefficient assessed the 
relationship between [Hb] and tHb-mass, allowing adjustment for PV (ml). 
Linear regression assessed the proportion of variance in tHb-mass explained by 
[Hb], allowing adjustment for PV (ml). In both correlation and regression 
analyses [Hb] and tHb-mass are expressed in g.l-1 and grams, respectively and PV 
in ml.  This is also the case elsewhere, unless otherwise stated.   
 
Differences across sub-groups were assessed by one-way analysis of variance 
(ANOVA), prior to which the assumption of normality was tested by the 
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Levene’s test for homogeneity of variances.  Where homogeneity of variance was 
verified, being the case for [Hb], Hct, tHb-mass (g), PV (%) and weight, a one-
way ANOVA was performed, with post hoc comparisons by Gabriel’s test due to 
the slightly different sample sizes across sub-groups. When homogeneity of 
variance was violated, as was the case for PV (ml & ml.kg-1), age and tHb-mass 
(g.kg-1), a Welch ANOVA 21 was used with post hoc comparisons made by the 
Games-Howell test, as this does not rely on the assumption of equal variances. 22 
All tests were two-sided with statistical significance being accepted as a p-value 
of < 0.05. 
 
Power calculation 
The power calculation was based on the study by Hinrichs and colleagues 23 and 
was performed using G*3 Power version 3.1.9.2. 24 According to Hinrichs and 
colleagues, the relationship (expressed as Pearson’s correlation coefficient) 
between [Hb] and tHb-mass was r= 0.59, p< 0.05.  Based on this, using a two-
tailed correlation: bivariate normal model, we calculated that 21 patients would 
provide 80% power at the 5% significance level to detect a correlation of at least 
r= 0.59 between [Hb] and tHb-mass. Given that five groups were studied, a total 
of 105 participants were required.  
 
Ethical approval 
Ethical approval was granted by the London- Camden and Kings Cross Research 
Ethics Committee (REC reference: 13/LO/1902).  Written informed consent was 
obtained from all participants. 
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Results  
One hundred and nine patients (61% male: mean (IQR) age 52 (36-64) years) 
consented to take part in the study.  Supplementary Figure 1 shows a 
Consolidated Standards of Reporting Trials (CONSORT) flow diagram indicating 
included and excluded patients and sub-groups. Sixteen patients were tested at 
Southampton General Hospital, ninety at UCLH (including HV) and three at the 
Royal Free Hospital (RFH). Surgical specialties are shown in Supplementary 
Table S1 online with patient characteristics and etiology of disease for IBD 
patients in Supplementary Table S2.  Patient characteristics, medications and 
etiology of CLD and CHF are shown in Supplementary Table S3 and Table S4 
online, respectively.  There were no differences in weight between sub-groups. 
Healthy volunteers (n= 21) were younger compared to all patient groups (p< 
0.0001) with CHF patients (n= 22) being older than IBD (n= 21, p= 0.001), 
surgical (n= 28, p= 0.008) and CLD patients (n= 16, p= 0.002).  Figure 1 A-D 
shows hematological variables and Figure 2 A-B plasma volumes across different 
sub-groups.   
 
Hemoglobin concentration 
Hemoglobin concentration was 128.4 ± 18.1 g.l-1 in the subjects overall. Across 
sub-groups, CLD patients had lower [Hb] when compared to HV and other 
disease groups (p< 0.0001, Figure 1B). Anemia prevalence (n=34 [39%]) varied 
across disease sub-groups (CLD 15 [94%], CHF 12 [55%], IBD 2 [9%], surgical 
5 [18%]). Amongst healthy volunteers, 5 (24%, all female) were anemic.   
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Total hemoglobin mass 
Mean ± SD tHb-mass was 669 ± 181 grams (8.5 ±1.9 g.kg-1 body mass) in 
subjects overall, with no statistically significant differences across sub-groups 
(Figure 1, C, D).  tHb-mass was higher in males than females: (758 ± 152 vs. 533 
± 132 g, p< 0.0001; and 8.9 ± 1.8 vs. 7.9 ± 2.0 g.kg-1, p= 0.006, respectively).   
 
Plasma volume 
Mean ± SD plasma volume was 3667 ± 1020 ml (47.1 ± 11.3 ml.kg-1) in subjects 
overall. PV was higher in males than females (4040 ± 1038 vs. 3093 ± 672 ml 
respectively, p< 0.0001), but not when weight adjusted (47.6 ± 11.3 vs. 46.2 ± 
11.5 ml.kg-1, p= 0.556). It also differed across disease groups, being expanded 
and more varied in CLD (4965 ± 1447 ml) compared to HV (3429 ± 538 ml, p= 
0.006), IBD (3202 ± 653 ml, p= 0.002) and surgical patients (3297 ± 590 ml, p= 
0.003), but not CHF (3883 ± 953 ml, p= 0.100).  Adjusted for body weight, PV 
was similarly expanded in CLD (59.1 ± 16.0 ml.kg-1) when compared to IBD 
(42.5 ± 8.3 ml.kg-1, p= 0.008) and surgical patients (41.3 ± 7.8 ml.kg-1, p= 0.004), 
but again was similar to that in CHF patients (48.6 ± 9.2 ml.kg- 1, p= 0.172) or 
HV (49.1 ± 7.9 ml.kg- 1, p= 0.191).  
 
Hemoglobin concentration was influenced by the degree of PV expansion (Figure 
4A), being lower in patients with severe PV expansion (n= 46, 119.0 ± 17.7 g.l-1) 
than mild to moderate PV expansion (n= 36, 131.1 ± 13.8 g.l-1, p= 0.005), and 
normal PV (n= 24, 140.7 ± 15.5 g.l-1, p< 0.0001), but not PV contraction (n= 3, 
143.8 ± 11.8 g.l-1, p= 0.139) 
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Relationships between hemoglobin concentration and total hemoglobin mass 
In the study cohort as a whole, [Hb] (g.l-1) correlated with tHb-mass (g) (r= 0.500, 
p< 0.0001, n= 109), this being true in both males (r= 0.452, p< 0.0001) and 
females (r= 0.462, p< 0.0001). Whilst true in HV and in IBD and surgical 
patients (r= 0.871, p< 0.0001; r= 0.687, p< 0.0001; and r= 0.763, p< 0.0001 
respectively; Figure 3 A-E) this was not the case in patients with CLD or CHF 
(r= 0.410, p= 0.114 and r= 0.312, p= 0.157, respectively).  
 
Whilst consistently statistically significant, the strength of the relationship 
between [Hb] and tHb-mass weakened as plasma volume rose, r-values falling 
from 0.94 to 0.91, 0.86 and 0.57 for those with low (n=3), normal (n=24), mild-
moderately expanded (n=36) and severely expanded (n= 46) plasma volumes 
respectively (p= 0.216 for the 3 with low PV, and p<0.0001 for the others). Sub-
group analysis is hampered by small numbers, but data are presented in 
Supplementary Table S5 online for completeness.  
 
Total hemoglobin mass, plasma volume and hemoglobin concentration on an 
individual level 
The data presented thus suggest that, at an individual level, [Hb] was not a good 
guide to tHb-mass- being strongly influenced by PV. This is illustrated in Figure 
5 A-E, which shows data from individual participants ranked by weight-adjusted 
tHb-mass from smallest to largest with corresponding PV (ml.kg-1) and [Hb] (g.l-
1) in HV (A), IBD (B), surgical (C), CLD (D) and CHF (E) patients, respectively. 
These show that patients who share a very similar tHb-mass may exhibit 
 13
markedly different [Hb] due to differences in PV. For example, in patients with 
IBD (Figure 5B), patient numbers 17 and 18 have a very similar tHb-mass (9.2 
g.kg-1 and 9.3 g.kg-1, respectively), yet one is defined as having a high normal 
[Hb] (161 g.l-1) and the other as being anemic ([Hb] 107 g.l-1), due to substantial 
differences in PV (37.2 ml.kg-1vs 65.7 ml.kg-1).  Similarly, in CLD patients 
(Figure 5E), tHb-mass in patient numbers 2 and 3 are the same (5.2 g.kg-1) but the 
first is considered to have a normal [Hb] (110 g.l-1), but the second to be 
markedly anemic ([Hb] 69 g.l-1) due to a relatively raised PV in the latter (36.5 
vs. 67.8 ml.kg-1 respectively).  
 
Linear regression models 
In the whole population, tHb-mass explained 25.0% of the variance in [Hb] 
(adjusted R2 = 0.250, p< 0.0001). However, tHb-mass explained different 
amounts of the variance in [Hb] across patient groups, adjusted R2 for HV, 
surgical and IBD patients being 0.746, 0.565 and 0.446 respectively (p< 0.0001 
in all cases). Of particular note, tHb-mass did not significantly explain variance in 
[Hb] in the two patient groups most likely to suffer expanded plasma volume and 
shifts in fluid- CLD (adjusted R2= 0.109, p= 0.114) or CHF patients (adjusted 
R2= 0.052, p= 0.157). In keeping, PV independently accounted for a greater 
proportion of the variance in [Hb] in these groups (R2 change 0.724 in CHF and 
0.805 in CLD) than in HV (0.192), surgical patients (0.374) or IBD patients 
(0.479) (p<0.0001 in all cases).  
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Hematological variables by anemia status 
In the 39 anemic subjects (mean ± SD [Hb] 109.6 ± 12.5 g.l-1), when compared to 
the 70 non-anemic ([Hb] 138.9 ± 10.6 g.l-1), tHb-mass (g & g.kg-1) was 
significantly lower (594 ± 192 vs. 711 ± 162 g, p= 0.001; 7.7 ± 1.9 vs. 9.0 ± 1.8 
g.kg-1, p= 0.001). However, PV (ml, and ml.kg-1) was also significantly higher in 
anemic subjects (4083 ± 1351 vs. 3434 ± 686 ml, p= 0.007; 52.6 ± 12.2 vs. 44.0 ± 
9.6 ml.kg-1, p< 0.0001: (see Table 1). 
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Discussion  
We have studied the contribution of changes in circulating hemoglobin and 
plasma volume to differences in the concentration of circulating hemoglobin. We 
have done so in healthy volunteers and across a variety of disease states, selected 
to be more or less likely to influence intravascular fluid status.  By doing so, we 
have shown that (i) variation in plasma volume contributes significantly to 
variation in hemoglobin concentration, (ii) this contribution is greater in cases of 
chronic liver disease of heart failure- diseases in which changes in total body 
water and in its distribution are more likely to occur, and (iii) perhaps most 
importantly, this may lead to some individuals being diagnosed as anemic whilst 
having a tHb-mass which is normal or even supra-normal.   These findings are of 
direct clinical relevance. A basic medical education teaches that plasma volume 
may be expanded in some disease states. But it is rarely if ever mentioned that 
this might lead to hemodilution of such degree as to cause anemia. Thus, a 
diagnosis of anemia generally leads to investigation of a cause for reduced 
hemoglobin synthesis or increase erythrocyte destruction or loss.  When such 
features are not identified, a diagnosis of ‘anemia of chronic disease’ is likely 
made. Rarely if ever is hemodilution considered as a cause, and measurement of 
tHb-mass or plasma volume performed. This is exemplified by the fact that no 
such measurements had been performed electively in the patients we studied. 
Such deficits in consideration or action may in part relate to the difficulty and 
expense of measuring such variables through traditional methods (radiolabelling 
of red blood cells, for instance). 
 
 
 16
Thus,  tHb-mass was generally strongly related to [Hb] (r ≥0.687 and p <0.0001 
in all cases); tHb-mass explained a good deal of the variance in [Hb] (adjusted R2 
in HV, surgical and IBD patients being 0.746, 0.565 and 0.446 respectively, p< 
0.0001 in all cases); and PV independently accounted for only a small proportion 
of the variance in [Hb] over that due to tHb-mass (R2 change 0.192, 0.374) or 
0.479 in HV, surgical and IBD patients respectively). By contrast, in the two 
patient groups most likely to suffer expanded plasma volume (CLD and CHF), 
tHb-mass did not correlate with [Hb] (r= 0.410, p= 0.114; r= 0.312, p= 0.157, 
respectively). Likewise, tHb-mass did not significantly explain variance in [Hb] 
(adjusted R2= 0.109, p= 0.114; adjusted R2= 0.052, p= 0.157, respectively), 
whilst PV independently accounted for a greater proportion of the variance in 
[Hb] over and above tHb-mass in these groups (R2 change 0.724 in CHF and 
0.805 in CLD). Thus, [Hb] is strongly influenced by disease-related changes in 
PV. The relationship between [Hb] and tHb-mass weakened as plasma volume 
rose (r-values falling from 0.94 and 0.91 in those with low or normal PV, to 0.57 
amongst those in whom PV was severely expanded.  
 
 
As a consequence, even amongst those in our small sample, we identified patients 
with identical and normal tHb-mass, in some of whom severe anemia would be 
diagnosed, likely triggering investigations focused upon failed erythrogenesis or 
increased red cell destruction. As specific exemplars of the phenomenon, two 
IBD patients had similar tHb-masses (9.2 and 9.3 g.kg-1), one having a high 
normal [Hb] (161 g.l-1) and the other being anemic ([Hb] 107 g.l-1), due to 
substantial differences in PV (37.2 ml.kg-1 vs. 65.7 ml.kg-1).  Similarly, two CLD 
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patients had the same tHb-mass (5.2 g.kg-1), one having a normal [Hb] (110 g.l-1), 
but the second being markedly anemic ([Hb] 69 g.l-1) due to a relatively raised PV 
in the latter (36.5 vs. 67.8 ml.kg-1 respectively).  
 
Our findings are thus of real clinical importance, as a significantly low [Hb] can 
trigger a raft of (unwarranted) investigations (such as the assay of circulating 
hematinic factors) or treatments (such as the administration of packed red blood 
cells), whilst denying the administration of agents to reduce plasma volume, 
which might sometimes be required. Blood transfusion itself carries risks 25 as 
well as a price in terms of healthcare costs. Meanwhile, in other circumstances, 
contraction in plasma volume might offer false reassurance by maintaining [Hb], 
when tHb-mass is low. 
 
Whilst tHb-mass is generally used as an index of oxygen carrying capacity and of 
circulating red cell mass, others have previously reported total circulating red 
blood cell volume (RCV) in this regard. In hematologically normal control 
subjects, hematocrit (Hct) in the 20-50% range reportedly correlated well with 
RCV (determined by 51Cr labeling of RBCs: r= 0.880, p< 0.001). 26 However, 
this relationship was disturbed when Hct fell outside this range, owing to wider 
variability in PV. Such data support those from other radiolabelling studies in 
suggesting that direct measurement of RCV (rather than the use of [Hb] or Hct) is 
required for the accurate diagnosis of polycythemia. 27 Likewise, data derived 
from the same technique which we applied (oCOR) show PV to be expanded 
(variably, but along with increased RCV) in polycythemia rubra vera.  28 
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The focus of such studies differed from ours: namely, they sought to address the 
degree to which variation in PV altered the accuracy of the diagnosis of 
polycythemia, whilst we assessed the influence of variation in tHb-mass and PV 
on [Hb] per se and on the diagnosis of anemia. Nor have any studies in this field 
been comprehensive across disease states, or assessed tHb-mass (rather than 
RCV). Nonetheless RCV (by 51Cr labeling) has been shown to be similar in 
anemic and non-anemic CHF patients, suggesting that PV expansion accounted 
for this diagnosis. 15 Indeed, this has been shown to occur (using I131-labeled 
albumin) in CHF due to systolic dysfunction, with poor correlation between [Hb] 
and RCV. 29 Likewise, and using the same technique, Miller showed 19 of 32 
patients hospitalized with decompensated CHF to be anemic, with only 4 of these 
having a true reduction in RCV. 30 Using the carbon monoxide rebreathing 
method, we extend such observations (see Table 2). Overall, 39 of the 109 
participants were anemic, in only 2 (13.3%) of whom was this due to a reduced 
tHb-mass [352 g and 449 g] in the context of a normal PV. In the remaining 
86.7%, reduced [Hb] was accounted for by PV expansion (n= 4 mild to moderate, 
tHb-mass 494 ± 76 g, and n= 8 severe, tHb-mass 539 ± 105 g).  Interestingly, 14 
of the 39 anemic patients (93%) had a relatively raised tHb-mass, with PV 
elevated to a greater degree (n= 1 mild to moderate PV expansion (tHb-mass 610 
g), n= 13 severe PV expansion (tHb-mass 758 ± 220 g).    
 
The overall prevalence of anemia for our study participants (36%) is similar to 
that reported in previous studies in non-cardiac surgical patients (30.4%). 9 Nine 
per cent of IBD patients suffered anemia, which is less than has been reported 
across European Countries (24%). 12 Some 54% of CHF patients suffered anemia 
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in the current study, somewhat more than has been previously reported in the 
Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry 
(34%), 31 or in patients with advanced HF (30%), 32 but in keeping with the data 
of others (55.6% 33 to 61%). 34  Of CLD patients, 94% suffered anemia- a figure 
somewhat higher that that previously reported by some (50-75%), 35,36 but in 
keeping with data in decompensated CLD (86%) 37 or hepatitis C infection 
(75%). 38   
Amongst healthy volunteers, five (24% of healthy volunteers) were anemic- a 
figure in keeping with global data relating to non-pregnant females (30%), 2 and 
only slightly higher than the 16% reported in non-pregnant women aged 15-49 
years from high income regions and 22% in menstruating women from central 
and eastern Europe. 39 This may be related to volunteering bias in the current 
study whereby those who thought they might be anemic preferentially applied to 
participate.  
 
This study utilized the optimized carbon monoxide rebreathing method, validated 
against 51Chromuim radiolabelling methodologies. 40 An advantage of our study 
was its assessment of diverse patient groups. Sample sizes, whilst small, were 
appropriately powered to explore the relationship between tHb-mass and [Hb]- 
albeit that, for administrative reasons, the sample size for patients with CLD (n= 
16) was below the 21 we originally sought, based on the study by Hinrichs and 
colleagues. 23 Nonetheless, we were yet able to demonstrate that PV changes in 
this group do influence assessed [Hb] and anemia diagnoses. 
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Differing blood sample methods (capillary and venous) yield identical ∆%COHb 
(and thus tHb-mass) values. 41 However, capillary [Hb] can be marginally higher 
than that in venous blood. 42-45 The use of differing sampling techniques across 
testing sites may thus have contributed a little to variation in measured [Hb], 
although capillary blood [Hb] values were all corrected to venous conditions, and 
all blood samples were collected from the same anatomical site, and with patients 
in the same posture (seated). This factor does not therefore weaken the 
significance of our findings. Whilst the use of different blood gas machines and 
testing staff may have introduced error in the measurement of tHb-mass, we 
found a typical error (TE) of repeat tHb-mass measurements of 1.93% (95% CI 
1.3-3.4%: unpublished data), values in keeping with other institutions using the 
oCOR method. 19, 46 
 
Finally, the oCOR method is quick and simple, avoids the technical difficulties of 
working with radiolabelled compounds, 40 offers a minimal burden for patients, is 
minimally invasive and is safe even in patients with serious medical conditions 
and comorbidities such as stable coronary artery disease. 47 This greatly widens 
the applicability of the oCOR test to measure tHb-mass and plasma volume in the 
clinical setting. To date, its clinical experimental application has been sparse- 
(e.g. to demonstrate that low tHb-mass may account for impaired exertional 
performance in otherwise healthy diabetics. 48 Whilst (rarely yet) applied to the 
measurement of red cell mass in patients with polycythemia rubra vera, 28 it has 
yet to be utilized in routine clinical practice but might find great value, for 
example in the estimation of red cell mass and plasma volume in cases of 
presumed excessive erythrocytosis. Our data might support wider use. 
 21
 
In conclusion, measured [Hb], and the diagnosis of anemia, can be strongly 
influenced by (or can largely depend upon) changes in plasma volume. The scale 
of this impact may be greater in some diseases than others. Constraining 
investigation of anemia to the identification of causes of reduced Hb synthesis or 
of erythrocyte loss or destruction may be inappropriate for many. The concept of 
‘anemia’ may thus need refining in clinical practice, and the oCOR method may 
support better and more appropriate assessments of the factors influencing 
circulating [Hb].   
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     Tables  
 
     Table 1. Hematological variables in anemic and non-anemic participants.  
Variable Anemic (n= 39) Non-anemic (n= 70) P-value 
[Hb] (g.l-1) 109.6 ± 12.5 138.9 ± 10.6 < 0.0001 
Hct (%) 35.0 ± 5.9 42.4 ± 3.0 < 0.0001 
tHb-mass (g) 594 ± 192 711 ± 162 0.001 
tHb-mass (g.kg-1) 7.7 ± 1.9 9.0 ± 1.8 0.001 
BV (ml) 5978 ± 1837 5606 ± 1146 0.257 
BV (ml.kg-1) 77.3 ± 16.7 71.6 ± 14.8 0.066 
PV (ml) 4083 ± 1351 3434 ± 686 0.007 
PV (ml.kg-1) 52.6 ± 12.1 44.0 ± 9.6 < 0.0001 
PV (%) 68% 61% < 0.0001 
RCV (ml) 1894 ± 692 2171 ± 501 0.018 
RCV (ml.kg-1) 24.7 ± 7.1 27.5 ± 5.7 0.023 
MCV (fl) 88.0 ± 6.2 91.0 ± 6.6 0.038 
MCH (pg) 29.3 ± 2.9 30.1 ± 2.2 0.218 
MCHC (g.l-1) 333.1 ± 18.0 330.5 ± 12.2 0.477 
RDW (%) 14.5 ± 1.7 13.7 ± 1.1 0.024 
Creatinine (μmol.l-1) 114.9 ± 117.4 84.3 ± 58.2 0.166 
Albumin (g.l-1) 37.4 ± 8.7 43.7 ± 4.9 0.001 
[Hb], Hemoglobin concentration; Hct, hematocrit; tHb-mass, total hemoglobin mass; 
BV, blood volume; PV, plasma volume; RCV, red cell volume; MCV, mean 
corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean 
corpuscular hemoglobin concentration; RDW, red cell distribution width.  Anemia 
defined according to World Health Organization criteria ([Hb] <130 g.l-1 in men and 
<120 g.l-1 in women.  Data are presented as mean ± SD, or frequency (%). 
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Table 2. Anemia classification based on hemoglobin concentration, red cell volume and plasma volume in all patients (n= 109). 
Anemia status  Normal PV Mild to moderate PV 
expansion 
Severe PV 
expansion 
PV 
contraction 
Total 
Non anemic Normal RCV 12 8 1 1 22 
 RCV deficit 4 1 0 2 7 
 RCV excess 5 17 19 0 41 
 Total 21 26 20 3 70 
Anemic Normal RCV 1 5 5 0 11 
 RCV deficit 2 4 8 0 15 
 RCV excess 0 1 13 0 14 
 Total 3 10 26 0 39 
Normal BV, PV and RCV were classified as derived volumes from measured tHb-mass within ± 8% of the expected normal volumes on an 
individual level. Mild to moderate volume expansion was considered >8% to <25% deviation from expected norms, and severe as >25% of the 
expected normal volume.  BV, blood volume, PV, plasma volume, RCV, red cell volume. Anemia defined according to World Health 
Organization criteria ([Hb] <130 g.l-1 in men and <120 g.l-1 in women.  Values are expressed as counts 
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Figure legends 
 
Figure 1. Hematological variables in healthy volunteers and patient sub-groups.  
Hct (%), hematocrit percentage (A); [Hb], hemoglobin concentration (B); tHb-
mass, total hemoglobin mass (g & g.kg-1) (C & D). HV, healthy volunteers; IBD, 
inflammatory bowel disease; HF, heart failure; LD, liver disease. *p< 0.0001 for 
Hct and [Hb] in LD patients compared to all other groups.  No differences in tHb-
mass (g or g.kg-1) between groups.  Data expressed as mean (± standard deviation 
error bars). 
 
Figure 2.  Plasma volume in healthy volunteers and patient sub-groups.  Plasma 
volume (ml & ml.kg-1) (A & B). HV, healthy volunteers; IBD, inflammatory 
bowel disease; HF, heart failure; LD, liver disease; PV, plasma volume. (A) PV 
(ml) between LD and HV, *p= 0.006, PV (ml) between LD and IBD, **p= 0.002 
and PV (ml) between LD and surgical patients, †p= 0.003; (B) PV (ml kg-1) 
between LD and IBD, *p= 0.008, PV between LD and surgical patients, **p= 
0.004.  Data expressed as mean (± standard deviation error bars). 
 
Figure 3.  Unadjusted relationship between hemoglobin concentration and total 
hemoglobin mass.  Healthy controls (A, n= 21), patients with IBD (B, n= 22), 
surgical patients (C, n= 28), liver disease (D, n= 16) and HF (E, n= 22). tHb-mass 
(g), total hemoglobin mass; [Hb] (g.l-1), hemoglobin concentration; IBD, 
inflammatory bowel disease; HF, heart failure. 
 
Figure 4. Hemoglobin concentration and hematocrit in all patients categorized by 
plasma volume status.  Plasma volume contraction (n= 3) was classified as > 
minus 8% from expected norms. Normal PV (n= 24) was classified as derived PV 
within ± 8% of the expected normal volume on an individual level. Mild to 
moderate volume expansion (n= 36) was considered >8% to <25% deviation from 
expected norms, and severe PV expansion (n= 46) as >25% of the expected 
normal volume. *p= 0.005 for [Hb] in severe PV expansion vs. mild to moderate, 
†p< 0.0001 for [Hb] in severe PV expansion vs. normal PV. PV, plasma volume; 
[Hb], hemoglobin concentration (g.l-1); Hct (%), hematocrit percentage. Data 
expressed as mean (± standard deviation error bars). 
 
 Figure 5. Individual participant data for total hemoglobin mass, plasma volume 
and hemoglobin concentration.  Participants ranked by tHb-mass (g.kg-1) (dark 
grey bars) from smallest to largest with corresponding PV (ml.kg-1) (light grey 
bars) and [Hb] (g.l-1) (black circles) in healthy volunteers (A), inflammatory 
bowel disease (B), surgical (C), chronic heart failure (D), and chronic liver 
disease (E). tHb-mass, total hemoglobin mass; PV, plasma volume; [Hb], 
hemoglobin concentration. 
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Participant recruitment and testing sites 
Patients were recruited from those managed at University College Hospital (University 
College London Hospitals NHS Foundation Trust, UCLH), Southampton General 
Hospital (University Hospital Southampton NHS Foundation Trust) and the Royal Free 
Hospital (Royal Free London NHS Foundation Trust, RFH). Supplementary Figure 1 
shows a Consolidated Standards of Reporting Trials (CONSORT)- style flow diagram 
indicating included and excluded patients and specific sub-groups.  HV, patients with 
IBD and those awaiting surgery were recruited from and tested at UCLH only. Patients 
with CLD were recruited from and tested at all three sites, and those with CHF at UCLH 
and Southampton. Healthy volunteers were members of staff at UCLH or University 
College London (UCL) recruited by word of mouth or email advertisement.  Patients 
were identified and recruited at outpatient clinics or when attending other routine clinical 
appointments.   
 
Eligibility criteria 
Inclusion criteria for all participants were, age >18 years, and ability give informed 
consent and to comply with basic breath-holding instructions.  Healthy volunteers were 
additionally free from known chronic disease or use of regular medications. In CHF 
(clinically diagnosed and under treatment, confirmed- as clinically indicated- by the 
presence of a circulating concentration of B-type natriuretic peptide (BNP) >200 pg ml-
1), additional inclusion criteria were echocardiographic or cardiac magnetic resonance 
imaging (cMRI) evidence of left ventricular (LV) systolic impairment as defined by a left 
ventricular ejection fraction of less than 50%; New York Heart Association (NYHA) 
class II-IV; and not fully stabilised, i.e. still symptomatic with shortness of breath and/or 
peripheral oedema and/or clinical signs of bibasal crepitations or peripheral oedema.  
Patients with CLD all had a diagnosis of alcoholic liver disease, primary sclerosing 
cholangitis, hepatitis C or cryptogenic cirrhosis. A confirmed diagnosis of IBD (either 
Crohn’s disease or ulcerative colitis) was required for inclusion into this group. For 
surgical patients, inclusion was based on a patient being scheduled to undergo elective 
major surgery, regardless of specialty.   
Excluded were prisoners, or those with a baseline %COHb greater than 5% (as can occur 
in smokers), presence of haemoglobinopathy.  
 
 
Blood sampling 
At UCLH and RFH, [Hb] was determined from a fingertip capillary blood sample (Hb 
201 Microvette, Hemocue AB, Angelholm, Sweden), analysed immediately (HemoCue® 
Hb 201+, Hemocue AB, Angelholm, Sweden) when [Hb] could not be obtained from 
venous blood at the time of testing or was not available on the same day as tHb-mass 
measurement from hospital electronic records. At UCLH and RFH, fingertip capillary 
samples (200 µl) were collected before and 6- and 8-min after the start of CO rebreathing 
(Na-heparinized 200 µl RAPIDLyte Multicap Capillary tubes, Siemens Healthcare 
Diagnostics Inc, Deerfield, USA), with samples analysed within 15 minutes for percent 
carboxyhaemoglobin (%COHb) using a blood gas analyser (Hemoximeter; Cobas b 221 
POC system, Roche Diagnostics Ltd, Switzerland). At Southampton, [Hb] was measured 
in venous blood. An intravenous cannula was inserted prior to tHb-mass testing at 
Southampton, allowing venous blood samples (200 µl) to be collected before and at 6- 
and 8-mins after CO rebreathing via a Na-heparinized blood gas syringe (RAPIDLyte, 
Siemens Healthcare Diagnostics Inc, Deerfield, USA). %COHb was determined at 
Southampton using the RAPIDPoint 500 Blood Gas System (Siemens Healthcare 
Diagnostics Inc, Deerfield, USA). All blood samples for the determination of [Hb], 
haematocrit (Hct) and %COHb were collected under the same conditions, from the same 
anatomical site, and with patients in a seated position.  Blood samples were analysed 
within 10-15 minutes of one another due to %COHb being analysed after the oCOR test 
using a blood gas machine (which takes 15 minutes). Blood sampling from venous, 
arterial and capillary blood yields an identical ∆%COHb and therefore identical tHb-
mass values. 1 
 
Calculation of tHb-mass 
tHb-mass was calculated using a specifically design excel spreadsheet (Microsoft Excel 
2011 for Apple Macintosh) using the formula: 
 
tHb-mass (g) = K x MCO(ml) x 100 x (Δ%COHb x 1.39)-1 
 
K = barometric pressure x 760-1 x [1(0.003661 x temperature)] 
MCO = COadm – (COsystem + lung (after disconnection) + COexhaled (after disconnection) 
COadm = CO volume administered into the system 
COsystem + lung (after disconnection) = CO concentration in spirometer x (spirometer volume + 
remaining volume in the lung after disconnection) 
COexhaled (after disconnection) = end-tidal CO concentration x alveolar ventilation x time 
Δ%COHb = difference between baseline %COHb and %COHb post CO administration 
(average of 6- and 8-min %COHb values) 
1.39 = Hufners number (constant) (ml CO x g Hb-1) 
 
where: 
lung residual volume, 1500 ml in men, 1200 ml in women; alveolar ventilation, 5000 ml 
min-1, CO concentration is in parts per million (ppm)  
 
Blood volume (BV), plasma volume (PV) and red cell volume (RCV) were calculated 
from mean corpuscular haemoglobin concentration (MCHC), [Hb] and tHb-mass, as 
below: 
 
BV (ml) = tHb-mass (g)/[Hb] (g.dl-1) • 100 
RCV (ml) = tHb-mass (g)/MCHC • 100 
PV (ml) = BV – RCV 
 
When Hct and [Hb] values were obtained from capillary blood at UCLH and the RFH 
these values were corrected to venous conditions using the following formulas 2, 3: 
[Hb] (g.dl-1) = [Hbcapillary] • 0.8787 + 1.24 
Hct (%) = [Hctcapillary] • 0.8425 + 5.23 
 
Estimation of normal adult values for PV were calculated using the formulas from the 
1995 Expert Panel on Radionuclides of the International Council for Standardisation in 
Haematology. 4 
Equation 1. Estimation of normal male plasma volume 
 
Mean normal PV (ml) = 1578 x S 
 
Equation 2. Estimation of normal female adult plasma volume 
 
Mean normal PV (ml) = 1395 x S 
Where S = body surface area (m2) calculated using the formula of Du Bois and Du Bois. 
5 
 
PV values were adjusted for age, sex, weight, and height using a published formula to 
calculate normal volumes as derived from >100,000 measurements of height and weight 
from Metropolitan Life tables. 6 Normal PV was classified as measured volumes within ± 
8% of the expected normal volume on an individual level. Mild to moderate volume 
expansion was considered >8% to ≤25% positive deviation from expected norms, and 
severe as >25% above the expected normal volume. 6 
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Supplementary Figure 1. Consolidated Standards of Reporting Trials (CONSORT)- style 
flow diagram indicating included and excluded patients and specific sub-groups.  Excluded 
patients are those who declined participation, failed to respond to correspondence via letter 
and telephone contact or could not be contacted despite multiple attempts by the research 
team.
Eligible patients 
approached for 
inclusion n= 499 
Chronic liver disease 
n= 16 
 
Excluded		
n=	390	
Patients included 
for analysis 
n= 109 
Surgical 
n= 28 
 
Healthy volunteers 
n= 21 
 
Chronic heart failure 
n= 21 
 
Inflammatory bowel disease 
n= 22 
 
 
Table-S1. Surgical specialty for planned surgical procedure (n= 28). 
Surgical specialty Frequency N (%) 
Upper gastrointestinal 8 (28.5%) 
Lower gastrointestinal 8 (28.5%) 
Orthopaedic 7 (25%) 
Other 3 (10.7%) 
Urology 2 (7.1%) 
 
 
 
 
Table-S2. Characteristics and aetiology of inflammatory bowel disease patients. 
Variable IBD (n= 22)   
Gender    
  Male (%) 50%   
Age (yr) 50 (33-62)   
Height (cm) 170.2 ± 7.3   
Weight (kg) 77.7 ± 18.1   
Aetiology of IBD    
Crohn’s disease 4 (18%)    
  Small bowel CD 2 (9%)   
  Terminal ileal CD 1 (4.5%   
Ulcerative colitis 9 (41%)   
  Ulcerative proctitis 3 (14%)   
  Pan UC 2 (9%)   
Collagenous colitis 1 (4.5%)   
IBD, Inflammatory bowel disease; CD, Crohn’s disease; UC, Ulcerative colitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-S3. Characteristics, medications and aetiology of liver disease patients. 
Variable LD (n= 16)   
Gender    
  Male (%) 75%   
Age (yr) 51 (48-55)   
Height (cm) 174.8 ± 8.9   
Weight (kg) 85.3 ± 18.5   
Primary aetiology of liver disease    
Hepatitis 3 (19%)   
ALD 8 (50%)   
Cryptogenic cirrhosis 2 (12%)   
Sclerosing cholangitis 2 (12%)   
Other 1 (6%)   
Hypertension 1 (6%)   
Medication    
  Beta blocker 3 (19%)   
  ACE inhibitor 0 (0%)   
  Statin 0 (0%)   
  Diuretic 5 (31%)   
Diuretic times per day    
  None 11 (69 %)   
  Once 5 (31 %)   
  Bi daily 0   
ALD, decompensated alcoholic liver disease; ACE inhibitor, angiotensin-converting-enzyme 
inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-S4. Characteristics, medications and aetiology of chronic heart failure patients. 
Variable CHF (n= 22)   
Gender    
  Male (%) 82%   
Age (yr) 68 (61-75)   
Height (cm) 173.5 ± 8.1   
Weight (kg) 80.4 ± 15.9   
Aetiology of heart failure    
Ischaemic heart disease 7 (32%)   
  Cardiomyopathy 10 (45%)   
  Ischaemic  5 (22%)   
  Non-ischaemic 5 (22%)   
Other 5 (22%)   
Hypertension 7 (32%)   
NHYA class    
  I 2 (9%)   
  II 14 (64%)   
  III 4 (18%)   
  IV 2 (9%)   
LVEF (%) 33.2 ± 11.4   
Medication    
  Beta blocker 19 (86%)   
  ACE inhibitor 20 (91%)   
  Statin 16 (73%)   
  Diuretic 17 (77%)   
  Diuretic dose (mg) 25 ± 29   
Diuretic times per day    
  None 5 (22%)   
  Once 14 (64%)   
  Bi daily 3 (14 %)   
NYHA, New York Heart Association Class; LVEF (%), left ventricular ejection fraction; 
ACE inhibitor, angiotensin-converting-enzyme inhibitor 
 
 
 
 
 
 
 
 
 
 
 
 
Table-S5. Relationship between total haemoglobin mass and haemoglobin concentration in 
sub-groups based on plasma volume status. 
 Plasma volume status 
Sub group Normal Mild to moderate Severe 
IBD (n= 9) 
r= 0.86, p= 0.003 
(n= 7) 
r= 0.94, p< 0.002 
(n= 5) 
r= 0.78, p= 0.118 
Surgical (n= 8) 
r= 0.94, p= 0.001 
(n= 14) 
n= 0.78, p= 0.001 
(n= 5) 
r= 0.80, p= 0.104 
CHF (n= 4) 
r= 0.95, p= 0.046 
(n= 6) 
r= 0.86, p< 0.029 
(n= 11) 
r= 0.59, p= 0.055 
HV (n=2) (n= 8) 
r= 0.91, p< 0.002 
(n= 11) 
r= 0.89, p< 0.0001 
r, Pearson’s correlation coefficient; PV values were adjusted for age, sex, weight, and height 
using a published formula to calculate normal volumes as derived from >100,000 
measurements of height and weight from Metropolitan Life tables. 6 Normal PV was 
classified as measured volumes within ± 8% of the expected normal volume on an individual 
level. Mild to moderate volume expansion was considered >8% to <25% deviation from 
expected norms, and severe as >25% of the expected normal volume. 6 Insufficient numbers 
to perform sub-group analysis in chronic liver disease group. IBD, inflammatory bowel 
disease; CHF, chronic heart failure; HV, healthy volunteers.  
 
